the treatment of acute myeloid leukemia

midostaurin, sold under the brand name rydapt, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (aml), myelodysplastic syndrome (mds) and advanced systemic mastocytosis. it is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium streptomyces staurosporeus.

the u.s. food and drug administration (fda) considers it to be a first-in-class medication.

aml and mds
midostaurin was found to be active against oncogenic cd135 (fms-like tyrosine kinase 3 receptor, flt3), in preclinical studies. clinical trials have primarily focused on relapsed/refractory aml and mds and have included single agent and combinati

we are bulk api vender of pkc412 from china.

https://www.tcsindustry.com/pro/100.html